Back to Gene
DOCK8 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

DOCK8 gene

The DOCK8 gene encodes a protein essential for the survival, structure, and movement of immune system cells.

Normal Function

The DOCK8 gene provides instructions for a member of the DOCK family of proteins, which act as guanine nucleotide exchange factors (GEFs). GEFs activate GTPases, which regulate the structural framework inside cells (the cytoskeleton). By controlling the cytoskeleton, these proteins influence cell structure and movement (migration).

DOCK8 is found most abundantly in immune system cells, including T cells, NK cells, and B cells. It helps maintain the structure and integrity of these cells and aids in their movement to sites of infection, particularly the skin. It also participates in signaling pathways that stimulate B cells to mature and produce antibodies.

Health Conditions Related to Genetic Changes

DOCK8 immunodeficiency syndrome

More than 130 mutations in the DOCK8 gene cause DOCK8 immunodeficiency syndrome (also called autosomal recessive hyper-IgE syndrome or AR-HIES). This disorder causes:

  • Recurrent severe infections of the skin and respiratory tract
  • Allergies, including food and environmental allergies
  • Asthma
  • An inflammatory skin disorder called eczema

Most mutations involve deletions of DNA, leading to a shortage or total absence of functional DOCK8 protein. This impairs immune cell development and function. Specifically, T cells lacking DOCK8 cannot maintain their shape when moving through dense spaces like the skin, causing them to die prematurely. The shortage of these cells and impaired B cell maturation weaken the immune response. Additionally, the condition is associated with higher-than-normal production of immunoglobulin E (IgE), which contributes to allergic reactions.

Other Names for This Gene

  • 1200017A24Rik
  • dedicator of cytokinesis protein 8 isoform 1
  • dedicator of cytokinesis protein 8 isoform 2
  • dedicator of cytokinesis protein 8 isoform 3
  • epididymis luminal protein 205
  • FLJ00026
  • FLJ00152
  • FLJ00346
  • HEL-205
  • MRD2
  • ZIR8

Frequently Asked Questions

Research is actively exploring gene‑replacement and gene‑editing strategies, such as CRISPR/Cas9‑mediated correction of the DOCK8 gene in autologous hematopoietic stem cells. Early‑phase clinical trials have shown promise, but these therapies are still experimental and not widely available. Patients interested in clinical trials should consult a specialized immunology center.
Patients are prone to recurrent skin infections (impetigo, cellulitis), viral infections (eczema herpeticum, molluscum contagiosum), and respiratory infections (pneumonia, bronchitis). Prevention strategies include: maintaining strict skin hygiene, promptly treating skin breaks, avoiding contact with individuals with active viral infections, using prophylactic antibiotics or antivirals as prescribed, and ensuring up‑to‑date vaccinations (including influenza and pneumococcal vaccines). Regular monitoring by an immunologist can help adjust preventive measures.
definitive diagnosis requires a combination of clinical evaluation, immunologic testing, and genetic analysis. First, a complete blood count with differential often shows elevated IgE and eosinophils. Flow cytometry can assess T‑cell, B‑cell, and NK‑cell numbers and function. The gold standard is sequencing of the DOCK8 gene to identify pathogenic variants; this can be done via targeted gene panels, whole exome sequencing, or whole genome sequencing. Functional assays, such as measuring cell migration or apoptosis in response to stimuli, may also support the diagnosis.
Management is multidisciplinary. Acute infections are treated with appropriate antibiotics, antivirals, or antifungals. Long‑term prophylaxis may include daily antibiotics (e.g., trimethoprim‑sulfamethoxazole) or antifungals (e.g., fluconazole). Immunoglobulin replacement therapy can help reduce infection frequency. For severe cases, hematopoietic stem cell transplantation (HSCT) offers a potential cure, but requires careful donor matching and conditioning. Gene‑editing approaches are under investigation but are not yet standard care.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab